Skip to main content
David Barillà on Muck Rack

David Barillà

As seen in: MDPI, Bisnow, Physician's Weekly, Multiple Sclerosis and Related Disorders, European Journal of Vascular and Endovascular Surgery, Annals of Vascular Surgery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Orlando State of the Market

|
By David Barillà
| Bisnow Verified
Why Attend Orlando State of the Market Orlando is in the midst of a modern land rush, with developers and investors rapidly targeting prime sites in one of the nation’s most dynamic commercial real estate markets. As population growth accelerates and new regulations reshape the landscape, understanding where to build, invest, and navigate evolving policies has never been more critical.
Open in Who Shared Issue with article?

Long-Term Results of Below-the-Knee Bypass Using a Prosthetic Graft with a Distal Arteriovenous Fistula Interposition

|
By Francesco Spinelli, David Barillà, Graziana Derone, Giuseppe Roscitano
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open in Who Shared Issue with article?

Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate. | Physician's Weekly

|
By Chieh-Hsin Lee, Bei Jiang, Maryam Nakhaei-Nejad, David Barillà
| Physician's Weekly
Relapsing-remitting multiple sclerosis (RRMS) is an autoimmune disorder of the central nervous system. Dimethyl Fumarate is a disease-modifying medication used to treat RRMS patients that can induce lymphopenia. We aimed to immunophenotype peripheral blood mononuclear cells (PBMC) in RRMS patients cross-sectionally and examine the characteristics and modifications of lymphopenia over time. Characterization of PBMC was done by multiparametric flow cytometry.
Open in Who Shared Issue with article?
See all 11 articles